Exploring 3 High Growth Tech Stocks in Switzerland

The Switzerland market started off on a firm note Thursday morning, but pared gains and very nearly slipped into the red by early afternoon, before recovering well to end the day’s session moderately higher. Investors digested the Swiss National Bank’s interest rate move, and awaited some key economic data from the U.S. The benchmark SMI ended with a gain of 61.24 points or 0.5% at 12,209.62, nearly 60 points off the day’s high of 12,267.86 The Swiss National Bank reduced its key policy rate by 25 basis points for the third straight meeting on Thursday, lowering it to 1% from 1.25%, as expected. Banks’ sight deposits held at the SNB will be remunerated at the SNB policy rate up to a certain threshold, and at 0.5% above this threshold, the bank said.

“Further cuts in the SNB policy rate may become necessary in the coming quarters to ensure price stability over medium term,” said bank in statement.

Swiss central bank sees inflation at

1

2%

this year down from previous forecast of

1

3%

projection for trimmed to

0

6%

from

11%

For

2026,

inflation is estimated compared projected June economic growth projected around unchanged outlook Swatch Group shares zoomed more than Richemont rallied VAT Group ended Julius Baer Logitech International Adecco Straumann Holding UBS Group gained Partners climbed Lonza notably Holcim ABB Sika Sandoz Sonova Schindler Ps Lindt Spruengli dropped about Novartis Givaudan lower SIG Kuehne Nagel Geberit also weak comments feedback contact editorial@rttnews.com Market Analysis #end# Segue into short comment about what makes good stock relation article topic current market conditions events above Don’t use em dashes Words avoid savvy delve

Top 10 High Growth Tech Companies In Switzerland

Click here to see the full list of 10 stocks from our SIX Swiss Exchange High Growth Tech and AI Stocks screener.

Let’s uncover some gems from our specialized screener.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ALSO Holding AG operates as a technology services provider for the ICT industry in Switzerland, Germany, the Netherlands, Poland, and internationally, with a market cap of CHF3.31 billion.

Operations: ALSO Holding AG generates revenue primarily from its operations in Central Europe (€4.62 billion) and Northern/Eastern Europe (€5.24 billion). The company provides a range of technology services within the ICT industry across multiple international markets.

ALSO Holding AG, amidst a challenging fiscal landscape marked by a 12.7% revenue drop to EUR 4.28 billion in the first half of 2024, still projects robust future growth. The company’s commitment to innovation is evident from its R&D investments, aligning with an anticipated earnings increase of 24.5% per annum, outpacing the Swiss market’s average. Recent presentations at the Baader Investment Conference highlighted strategic initiatives poised to harness this growth potential despite current volatility in earnings and share price fluctuations over the past three months.

The firm’s focus on expanding its technological capabilities could redefine its market stance, supported by forecasts that revenue will grow faster than the broader Swiss market at a rate of 12.7% annually. This strategic emphasis on R&D not only fuels ALSO Holding’s competitive edge but also positions it well within an industry shifting increasingly towards high-value digital solutions and services.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in developing products for oncology and anti-infectives, with a market cap of CHF570.91 million.

Operations: Basilea Pharmaceutica generates revenue primarily from the discovery, development, and commercialization of innovative pharmaceutical products, amounting to CHF149.02 million. The company focuses on addressing medical needs in oncology and anti-infectives.

Amidst a backdrop of regulatory wins and strategic R&D investment, Basilea Pharmaceutica AG is navigating its path in the high-stakes biotech arena. The company’s recent elevation of revenue guidance to CHF 203 million for 2024, up from CHF 190 million, alongside an expected net profit jump to CHF 60 million from CHF 42 million, underscores a robust financial trajectory. This uptick is bolstered by the extended market exclusivity for its antifungal Cresemba®, now including pediatric patients—a move that not only expands the drug’s market reach but also enhances its competitive edge with an additional two years of exclusivity until October 2027. Furthermore, Basilea’s commitment to innovation is reflected in its R&D spending which consistently aligns with industry advancements. With earnings projected to surge by an impressive 34.4% annually, Basilea stands out for its strategic foresight and operational agility in a challenging yet opportunistic sector.

Simply Wall St Growth Rating: ★★★★★★

Overview: Comet Holding AG, along with its subsidiaries, offers X-ray and radio frequency (RF) power technology solutions across Europe, North America, Asia, and globally, with a market cap of CHF2.58 billion.

Operations: Comet Holding AG generates revenue through three primary segments: X-Ray Systems (CHF115.34 million), Industrial X-Ray Modules (CHF95.90 million), and Plasma Control Technologies (CHF180.62 million). The company operates internationally, providing advanced technology solutions in Europe, North America, and Asia.

Comet Holding AG, amidst a challenging market, reported a notable improvement in its financial metrics for the first half of 2024. Sales dipped slightly to CHF 189.32 million from CHF 207.03 million year-on-year; however, net income more than doubled to CHF 4.06 million from CHF 1.94 million, reflecting enhanced operational efficiency and cost management strategies. This performance is underpinned by robust R&D investments that align with Comet’s strategic focus on innovation in high-tech sectors—critical as the company aims to maintain its competitive edge and capitalize on future growth opportunities highlighted by an expected annual profit surge of 48%.

Make It Happen

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com